Gastroparesis

Can Gastroparesis Be Misdiagnosed as IBS? Why Delayed Emptying Gets Missed

April 25, 202610 min readBy GLP1Gut Team
gastroparesisIBSmisdiagnosisgastric emptyingfunctional dyspepsia

📋TL;DR: Gastroparesis gets misdiagnosed as IBS because gastric emptying scintigraphy is not part of standard IBS workups. The symptom overlap with both IBS and functional dyspepsia is extensive. Idiopathic gastroparesis, which accounts for one-third of cases, is the most commonly missed form because patients lack an obvious risk factor like diabetes. Nausea as the dominant symptom is the strongest clinical signal that gastroparesis rather than IBS may be the diagnosis.

What We Know

  • Gastric emptying scintigraphy is not included in the Rome IV diagnostic algorithm for IBS, creating a systematic blind spot for gastroparesis (Lacy et al. 2016).
  • Up to 40% of patients referred for gastric emptying studies after failing IBS treatment have delayed emptying (Bharucha et al. 2015).
  • Functional dyspepsia and gastroparesis have overlapping symptoms and may represent a spectrum of the same pathophysiology rather than distinct diseases (Stanghellini et al. 2016).
  • Idiopathic gastroparesis accounts for approximately one-third of all gastroparesis cases and is the form most likely to be misclassified as IBS (Parkman et al. 2004).
  • Nausea is the dominant symptom in 90-95% of gastroparesis patients but is not a defining feature of IBS under Rome IV criteria (Hasler et al. 2011).

What We Don't Know

  • The true prevalence of gastroparesis among patients currently carrying an IBS diagnosis, because population-level gastric emptying screening has not been performed.
  • Whether functional dyspepsia and gastroparesis should be considered the same condition on a severity continuum or distinct entities with different management strategies.
  • How many patients with idiopathic gastroparesis would have been diagnosed earlier if gastric emptying studies were part of standard workups for chronic nausea with IBS-like symptoms.
  • Whether early diagnosis and treatment of mild gastroparesis prevents progression to more severe disease.
  • The optimal clinical criteria for deciding when an IBS patient should be referred for gastric emptying testing.

Gastroparesis gets missed in IBS patients for a structural reason: the test that detects it is not part of the IBS diagnostic process. The Rome IV criteria define IBS based on symptoms. A gastric emptying study, which is the only way to confirm gastroparesis, is not included in that algorithm. A patient with delayed gastric emptying who reports bloating, abdominal pain, and nausea can meet Rome IV criteria for IBS, receive the diagnosis, and start IBS treatment without anyone ever measuring how quickly food leaves their stomach. For idiopathic gastroparesis patients, who have no diabetes or surgical history to prompt motility testing, the misdiagnosis can persist for years.

Why does the standard IBS workup miss gastroparesis?

The standard IBS diagnostic pathway is designed to identify IBS and exclude dangerous conditions. The Rome IV criteria check symptom patterns. Bloodwork screens for celiac disease and inflammatory markers. A colonoscopy may be performed to rule out IBD or colorectal pathology. These steps are appropriate for their intended purpose, but none of them evaluate gastric motility. A gastric emptying study is a nuclear medicine test that requires a specialized meal, radioactive tracer, and serial imaging over 4 hours. It is not something ordered routinely. It is ordered when gastroparesis is specifically suspected.

The problem is that gastroparesis may not be suspected when the presenting symptoms are framed as IBS. A patient who reports bloating, pain, and altered bowel habits fits the IBS pattern. If the gastroenterologist does not specifically ask about upper GI symptoms like early satiety, postprandial fullness, and the character and timing of nausea, the gastroparesis signals may not emerge. Even when nausea is mentioned, it can be attributed to IBS or anxiety rather than prompting motility testing.

The functional dyspepsia overlap

The diagnostic picture is further complicated by functional dyspepsia (FD), another Rome IV-defined functional disorder that produces upper GI symptoms: postprandial fullness, early satiety, epigastric pain, and epigastric burning. Stanghellini and colleagues have argued that functional dyspepsia and gastroparesis may share underlying pathophysiology and represent different points on a spectrum rather than distinct diseases. In clinical practice, this means a patient may receive a functional dyspepsia diagnosis based on symptoms without undergoing a gastric emptying study, when they actually have measurable delayed emptying that would reclassify them as having gastroparesis.

The distinction matters because gastroparesis has specific treatments (prokinetics, pyloric interventions) that are not indicated for functional dyspepsia alone. A patient labeled with FD and treated with acid suppression and dietary changes may be missing out on prokinetic therapy that could meaningfully improve their symptoms. The same applies when the FD or gastroparesis symptoms are lumped under an IBS umbrella: the treatment approach changes if delayed emptying is confirmed.

Idiopathic gastroparesis: the most commonly missed form

Diabetic gastroparesis is the form most clinicians think of first. A patient with longstanding diabetes who develops nausea and vomiting will typically get a gastric emptying study because the clinician recognizes the risk. Post-surgical gastroparesis is similarly identifiable because the temporal relationship to surgery is usually clear. Idiopathic gastroparesis, which accounts for approximately one-third of all cases, is different. These patients have no diabetes, no surgical history, and no obvious red flag that prompts motility testing. They are otherwise healthy people with chronic nausea, bloating, and fullness who see their doctor, get labeled with IBS or functional dyspepsia, and are managed with symptom-directed therapies.

Some idiopathic gastroparesis cases may follow viral infections (post-viral gastroparesis), but the viral connection is often not established because the initial illness may have been mild or attributed to food poisoning. Without an identifiable cause to trigger suspicion, idiopathic gastroparesis blends into the functional GI disorder category and goes undiagnosed. Parkman and colleagues documented this pattern in the NIH Gastroparesis Clinical Research Consortium, finding that idiopathic patients had longer diagnostic delays than diabetic patients.

When nausea is the dominant symptom

Nausea is present in 90-95% of gastroparesis patients and is frequently rated as the most bothersome symptom (Hasler et al. 2011). In contrast, the Rome IV criteria for IBS do not include nausea as a diagnostic criterion. Nausea can occur in IBS patients, but it is typically secondary to the pain-bloating complex rather than the dominant complaint. When a patient's primary concern is persistent or meal-triggered nausea rather than abdominal pain related to bowel habits, the diagnostic suspicion should shift toward a gastric motility problem.

The clinical scenario that most often leads to misdiagnosis is a patient who presents with nausea, bloating, and variable bowel habits. The bloating and bowel habit changes meet IBS criteria. The nausea is noted but not pursued as a separate diagnostic signal. An IBS diagnosis is applied, and the nausea is managed with antiemetics or attributed to the IBS itself. Meanwhile, the delayed gastric emptying driving the nausea remains unidentified.

â„šī¸If you have been diagnosed with IBS and nausea is your most bothersome symptom, make sure your doctor knows this. Nausea as the dominant complaint should prompt evaluation for gastroparesis and should not be assumed to be part of IBS without a gastric emptying study.

Who is most at risk for gastroparesis being missed?

Several patient populations face higher risk of having gastroparesis misclassified as IBS.

  • Young women without diabetes. Idiopathic gastroparesis disproportionately affects women (4:1 ratio). A young woman with chronic nausea and bloating is statistically more likely to receive an IBS diagnosis than a gastric emptying study, despite being in the highest-risk demographic for idiopathic gastroparesis.
  • Patients with normal upper endoscopy results. An EGD that shows no obstruction, ulcers, or structural abnormalities is often interpreted as reassuring. However, a normal EGD says nothing about gastric motility. Gastroparesis is a functional motility problem, not a structural one, and requires a different test entirely.
  • Patients whose nausea is attributed to anxiety. Persistent nausea without an obvious organic cause is frequently attributed to anxiety or stress, especially in younger patients. While anxiety can cause nausea, gastroparesis should be excluded before a psychogenic cause is assumed.
  • Patients on medications that slow gastric emptying. Opioids, GLP-1 receptor agonists (semaglutide, liraglutide), and anticholinergics can cause or worsen gastroparesis. Patients on these medications may develop GI symptoms that are attributed to IBS or medication side effects rather than triggering a motility evaluation.
  • Patients with prior viral illness followed by chronic GI symptoms. Post-viral gastroparesis can mimic the same timeline as post-infectious IBS, and without a gastric emptying study, the two are clinically indistinguishable.

What to ask your doctor

If you suspect gastroparesis may be contributing to or explaining your IBS diagnosis, specific questions can move the evaluation forward.

  • "My nausea is worse than my bowel symptoms. Could delayed gastric emptying be causing this? Can we do a 4-hour gastric emptying study?" This directly communicates the symptom hierarchy and requests the appropriate test.
  • "I feel full after just a few bites and it feels like food sits in my stomach for hours. Is this consistent with gastroparesis?" Describing early satiety in specific terms gives your doctor concrete information to work with.
  • "My IBS treatments are not helping the nausea or early satiety. Have we ruled out gastroparesis?" This reframes the conversation from treatment adjustment to diagnostic reconsideration.
  • "I noticed my symptoms are much worse with solid foods but better with liquids and soups. Does that pattern suggest anything specific?" The solid-liquid differential is a classic gastroparesis pattern.
  • "If we do a gastric emptying study, can we make sure it is the full 4-hour protocol?" This is important because shorter studies miss approximately 30% of gastroparesis cases.

What happens when the misdiagnosis is corrected?

When gastroparesis is identified in a patient previously diagnosed with IBS, the treatment approach changes fundamentally. Dietary recommendations shift from low-FODMAP (which may include high-fiber, high-residue foods) to a gastroparesis-appropriate diet: low-fat, low-fiber, small frequent meals, with an emphasis on soft or pureed textures and adequate liquid intake. Prokinetic medications (metoclopramide, domperidone where available, low-dose erythromycin) may be prescribed to improve gastric emptying. Antiemetics are used more aggressively to manage nausea. IBS-specific medications like antispasmodics may be discontinued if they are not addressing the actual problem.

For patients who also have SIBO secondary to gastroparesis, antibiotic treatment for the SIBO combined with prokinetic therapy for the gastroparesis addresses both the bacterial overgrowth and the motility dysfunction that caused it. This combined approach has a better chance of sustained improvement than treating either condition in isolation.

Frequently Asked Questions

How common is gastroparesis in the general population?

Community-based studies estimate gastroparesis prevalence at approximately 1.8% in women and 0.6% in men, based on symptom assessment. However, the true prevalence is likely higher because many cases are undiagnosed. A population-based study by Jung and colleagues found that delayed gastric emptying was present in a meaningful proportion of people with upper GI symptoms who had not been formally diagnosed.

Can a normal upper endoscopy rule out gastroparesis?

No. Upper endoscopy (EGD) evaluates the structural integrity of the esophagus, stomach, and duodenum. It can detect ulcers, strictures, tumors, and other physical obstructions. It cannot assess gastric motility. A stomach that looks structurally normal on endoscopy can still empty abnormally slowly. Gastroparesis requires a gastric emptying study for diagnosis.

Does gastroparesis always cause vomiting?

No. Vomiting is common in moderate and severe gastroparesis but is not universal. Mild gastroparesis may present primarily with nausea, early satiety, and bloating without frank vomiting. The absence of vomiting does not rule out gastroparesis and should not be used as a reason to skip gastric emptying testing in a patient with other suggestive symptoms.

Can the same person have functional dyspepsia and gastroparesis?

This is an ongoing debate. Some researchers argue they are different points on a spectrum of gastric dysfunction rather than separate diseases. In clinical practice, a patient with functional dyspepsia symptoms who undergoes a gastric emptying study and shows delayed emptying would be reclassified as having gastroparesis. The distinction determines whether prokinetic therapy is appropriate.

Will losing weight help gastroparesis?

Weight loss is not a treatment for gastroparesis and can be a complication of it. Patients with moderate to severe gastroparesis often lose weight unintentionally because they cannot eat adequate amounts due to nausea and early satiety. If you are losing weight alongside chronic nausea and fullness, this is a reason to pursue diagnostic testing rather than a therapeutic goal.

âš ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Key Takeaways

  1. 1Gastric emptying studies are not part of the standard IBS workup, which means gastroparesis is systematically overlooked in patients diagnosed with IBS.
  2. 2Nausea as your dominant or most bothersome symptom should prompt evaluation for gastroparesis rather than acceptance of an IBS label.
  3. 3Idiopathic gastroparesis (no known cause) accounts for one-third of cases and is the form most likely to be missed because there is no obvious risk factor to prompt testing.
  4. 4The overlap between gastroparesis and functional dyspepsia means some patients may receive one label when the other is more accurate.
  5. 5If your symptoms are concentrated in the upper abdomen and worsen with solid food, ask specifically about a 4-hour gastric emptying study.

Sources & References

  1. 1.Bowel Disorders (Rome IV criteria for IBS) - Lacy BE et al., Gastroenterology (2016)
  2. 2.Epidemiology and natural history of gastroparesis - Bharucha AE et al., Gastroenterology Clinics of North America (2015)
  3. 3.Functional Gastroduodenal Disorders (Rome IV) - Stanghellini V et al., Gastroenterology (2016)
  4. 4.Gastroparesis: etiology, clinical features, and treatment - Parkman HP et al., Clinical Gastroenterology and Hepatology (2004)
  5. 5.Nausea and vomiting in gastroparesis: symptom severity and impact on quality of life - Hasler WL et al., Gastroenterology (2011)
  6. 6.ACG Clinical Guideline: Management of Gastroparesis - Camilleri M et al., American Journal of Gastroenterology (2018)
  7. 7.Gastroparesis: Overview - National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK (2024)

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare professional before making changes to your diet, medications, or health regimen. GLP1Gut is a tracking tool, not a medical device.

Figure Out What's Actually Triggering You

An AI-powered meal and symptom tracker that connects what you eat to how you feel, built specifically for people on GLP-1 medications experiencing digestive side effects.